Abstract PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …

Simple Summary Immune checkpoint blockade targeting PD-1/PD-L1 has a promising
therapeutic efficacy in different tumors, but a significant percentage of patients cannot benefit …

Cancer immunotherapies targeting immune checkpoints such as programmed cell-death
protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are …

Abstract PD-1/PD-L1 blockade appears to be a very promising immunotherapy with
significant clinical benefits and durable responses in multiple tumor types. However, the …

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …

PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-
PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD …

The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Cancer immunotherapy has greatly advanced in recent years, and PD-1/PD-L1 blocking
therapy has become a major pillar of immunotherapy. Successful clinical trials of PD-1/PD …

Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …